On May 24, 2013, the Department of Justice announced that ISTA Pharmaceuticals Inc., a subsidiary of Bausch+Lomb, pled guilty to felony charges of conspiracy to introduce a misbranded drug into interstate commerce in violation of the Federal Food, Drug and Cosmetic Act (FDCA) and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. As part of the settlement, ISTA agreed to pay $33.5 million to resolve criminal and civil liability resulting from its marketing of the drug Xibrom.
The ISTA settlement is the latest in a long line of pharmaceutical company settlements resulting from off-label promotion and illegal remuneration to physicians in exchange for writing prescriptions. This case further demonstrates that the government is not solely focused on Big Pharma as it selects which cases to prosecute. Compared to recent settlements involving dollar amounts running into the hundreds of millions and even billions of dollars, the ISTA settlement amount is relatively small. But that doesn’t mean that this enforcement action is not significant.
Quite to the contrary, this case sends a number of key messages to the pharmaceutical industry, not the least of which is the continued emphasis that the government places on the importance of evaluating the effectiveness of a compliance program.
As part of the plea agreement, Bausch+Lomb agreed to maintain a Compliance and Ethics Program. The agreement also requires that Bausch+Lomb’s President of Global Pharmaceuticals annually review the effectiveness of the Program. Based upon that review, the President must submit to the government a signed certification that the Program:
· Includes policies and procedures designed to prevent violations of the FDCA and Federal health care program requirements; and
· Was effective in preventing such violations.
The plea agreement does not dictate any specifics regarding the manner in which the Bausch+Lomb President must conduct the review. The certification, however, must include a summary of the President’s review.
The requirement to evaluate the effectiveness of a company’s compliance program is not new to the ISTA plea agreement. A number of Corporate Integrity Agreements (CIAs) and at least one other plea agreement (Abbott) require companies to review the effectiveness of their compliance programs. Some of these CIAs – namely the Bayer, Novartis, Forest, Ortho-McNeil-Janssen, and Synthes CIAs – require review by an independent compliance expert. The Bayer CIA went so far as to require review by an independent compliance expert panel, which must consist of three compliance experts.
The ISTA plea agreement requires that Bausch+Lomb’s Board of Directors also annually evaluate the effectiveness of the Compliance and Ethics Program. The Board can do this by receiving updates on the Compliance Officer’s activities and the implementation of the compliance program. Interestingly, the plea agreement specifically states that Board review does not require the retention of third party experts.
The Board also must submit to the government a Board Resolution summarizing its review and oversight of the compliance program which states its conclusion that Bausch+Lomb has implemented an effective compliance program.
In a future blog, I will explore some of the other points of significance of the ITSA settlement, including the companion Office of Inspector General (OIG) Divestiture Agreement that resulted in the exclusion of ISTA Pharmaceuticals from participation in Federal health care programs and requires ISTA to divest itself of all assets and operations to Bausch+Lomb.
November 24, 2014
Recently I was asked by a client whether they should continue to do Re-Qualifications or change to Continued Process Verification on their qualified cleaning circuits. To answer this, the factors to...
December 15, 2014
My last blog focused on the industry trends concerning cleaning validation verification. Through a quick poll we found that out of twenty-three respondents, approximately fifty (50) percent are doing...
February 5, 2015
ASTM E2500 – Risk-based testing has been in play for several years now. By design, there is a significant opportunity to avoid many lifecycle costs without creating an adverse impact to quality or...